Genmab faces trade secret misappropriation allegations from AbbVie regarding ADC pipeline products
From Nasdaq: 2025-03-21 23:46:00
Genmab A/S faces allegations of trade secret misappropriation by AbbVie Inc. AbbVie filed a complaint in a US District Court in Seattle, naming Genmab A/S, ProfoundBio US Co., ProfoundBio (Suzhou) Co., Ltd., and former AbbVie employees as defendants. The claims revolve around the misappropriation of AbbVie’s trade secrets involving the use of disaccharides to enhance the hydrophilicity of drug-linkers in ADCs. AbbVie seeks damages and injunctive relief, but is not asserting patent rights against the defendants. Genmab acquired ProfoundBio in May 2024, the company behind the ADC pipeline products in question.
Read more at Nasdaq: Genmab To Vigorously Defend Against AbbVie’s Trade Secret Misappropriation Claims